Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099006 · ClinicalTrials.gov registry record · Phase 2
Novel Topical Therapies for the Treatment of Genital Pain
A Phase 2 study of Female Genital Diseases, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02099006 is a Phase 2 study of Female Genital Diseases that has completed, run by University of Rochester. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02099006, a Phase 2 study of Female Genital Diseases, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Amitriptyline
- DRUG Loperamide
- DRUG Baclofen
- DRUG Ketoprofen
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099006
The ClinicalTrials.gov registry entry for NCT02099006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Female Genital Diseases appearing as the primary indexed condition, and to 5 interventions - of which Ketamine is the first listed.
NCT02099006 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02099006 about?
NCT02099006 is a clinical study titled "Novel Topical Therapies for the Treatment of Genital Pain". This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.
What is the current status of trial NCT02099006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-11. Estimated completion is 2015-06.
What conditions does trial NCT02099006 study?
This clinical trial studies the following conditions: Female Genital Diseases.
What interventions are being tested in trial NCT02099006?
The interventions under investigation include: Ketamine (DRUG), Amitriptyline (DRUG), Loperamide (DRUG), Baclofen (DRUG), Ketoprofen (DRUG).
Who is sponsoring clinical trial NCT02099006?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02099006 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.